Dexcom (DXCM) Shares Outstanding (2010 - 2026)

Dexcom (DXCM) has reported Shares Outstanding (Entity) for 17 consecutive years, with $377.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Shares Outstanding (Entity) fell 3.77% year-over-year to $377.4 million in Q2 2026; TTM through Jun 2026 was $377.4 million, a 3.77% decrease from a year earlier, with the FY2025 full-year figure at $384.8 million, down 1.51% from the prior year.
• Shares Outstanding (Entity) was $377.4 million for Q2 2026 at Dexcom, down from $385.9 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $400.7 million in Q2 2024 and troughed at $377.4 million in Q2 2026.
• A 5-year average of $389.1 million and a median of $388.8 million in 2023 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) gained 3.78% in 2024 and dropped 3.77% in 2026, its largest moves.
• Over 5 years, Shares Outstanding (Entity) stood at $386.3 million in 2022, then retreated by 0.23% to $385.4 million in 2023, then rose by 1.38% to $390.7 million in 2024, then declined by 1.51% to $384.8 million in 2025, then dropped by 1.92% to $377.4 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $377.4 million (Q2 2026), $385.9 million (Q1 2026), and $384.8 million (Q4 2025), per Business Quant data.